Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250414) titled 'A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis' on Oct. 6.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, prevention purpose
Primary Sponsor: Yamamoto Akiko
Condition:
Familial Pulmonary Fibrosis
Interstitial Lung Abnormalities
Interstitial Lung Diseases
Intervention:
Nerandomilast/Placebo matching nerandomilast
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 27/02/2026
Target Sample Size: 80
Countries of Recruitment...